Important information.

You are now entering the website of Hambro Perks Asset Management Limited.

The investments referred to in this website are not suitable for all investors. All potential investors will be required to declare that they fall within the definition of an exempt person as set out in the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. We do not provide investment, tax or legal advice and recommend you seek professional advice if you are considering investing with us. There is a risk that you may suffer a loss of any capital that you may choose to invest.

We invest in unquoted shares in small companies which are inherently illiquid and may be difficult to value or sell. EIS investments are only appropriate for investors with a medium to long term investment horizon. The timing and extent of realisations cannot be predicted and may take longer than five years. The tax reliefs associated with investing in EIS products depend on the individual circumstances of each investor and may be subject to change.

Past performance is not necessarily a guide to future performance and may not be repeated, and there is no guarantee that targets will be met. You should be aware that share values can go down as well as up and you may not get back all or any of the amount you originally invested.

I have read and understood this important information.

Accept & Proceed
Go Back

Funds.

There are a number of ways for investors to access Hambro Perks’ investment activities. Please contact the Hambro Perks Strategic Partnerships team at IR@hambroperks.com

Hambro Perks Leaders Fund.

The Leaders Fund backs great founders and businesses with conviction.

Hambro Perks Leaders Fund is our flagship primary venture capital fund, targeting post-revenue Seed and Series A technology companies in Europe.  We identify, invest in and help to build the next generation of market-leading companies, entrepreneurs and innovators.

With decades of combined investing experience, our team works with talented founders and entrepreneurs to support them as they become business leaders, innovating with game-changing products to help lead their industries in new directions, and have a positive impact on the world.

Many of our previous investments have gone on to become household names, making us the first-choice investment partner for founders.

Hambro Perks Growth EIS Fund.

The Hambro Perks Growth EIS Fund offers individuals, and other entities, the chance to co-invest alongside Hambro Perks in high growth, unlisted companies while benefitting from EIS reliefs (if eligible).

Investors in the Fund do not have to be able to benefit from EIS reliefs, and trusts, companies and overseas residents are welcome to invest. For more details on our portfolio please click below.

Co-Investment Fund Brochure

Hambro Perks Environmental Technology.

Hambro Perks Environmental Technology is a fund focussed on investing in emerging environmental technologies, and currently includes a portfolio of seven fast-growth technology companies, working to solve some of the most important environmental challenges faced by the world today.

Environmental technology is a sector which is set to experience enourmous growth on every continent, as we all look to reduce our impact on the planet and move towards solving important environmental challenges. Hambro Perks is partnering with real thought leaders within the space in order to focus on technology companies that have a positive impact on the world we live in.

Hambro Perks Special Opportunities .

Hambro Perks Special Opportunities Fund invests in US and UK high-growth technology companies.  The portfolio currently comprises 11 privately held stakes in companies operating in healthcare, biotechnology and life sciences, including:

Gelesis – Gelesis is a biotechnology company developing a novel category of therapies for GI-related chronic diseases. The Gelesis portfolio includes a product for obesity, and a pipeline with potential therapies for Non-alcoholic Fatty Liver Disease and Type 2 diabetes.

Vedanta – Vedanta Bioscience is developing a new category of therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria. It has four clinical-stage programs in development for solid tumors, high-risk CDI, food allergy, and IBD, and one preclinical discovery program for the prevention of infection and recurrence of several multi-drug resistant organisms.

Nexeon – Nexeon is a British business developing silicon anode battery technology to reduce carbon anode energy inefficiency. Nexeon’s technology makes a big difference to the real world performance of battery operated equipment, improving productivity and quality of life.

Hambro Perks Access Fund.

Hambro Perks Access Fund is a direct secondaries fund, investing in a diversified portfolio of secondary equity positions in growth businesses across Europe.

The fund offers liquidity to founders and early investors in companies which have reached growth stage, but have not yet achieved an exit. To date, has worked with some of the best-known and most successful founders in Europe.

Hambro Perks Asset Management Limited (HPAM Ltd) is a non-cellular company incorporated in Guernsey with Company number 64127 and registered office at Sarnia House, Le Truchot, St Peter Port, Guernsey GY1 4NA. HPAM Ltd is licensed under the Protection of Investors (Bailiwick of Guernsey) Law, 1987, by the Guernsey Financial Services Commission with reference number 2293289.

X

Share your business.

If you are looking for early stage investment, share your business with us.








X

General enquiry.





X

Subscribe to our newsletter.

We send out a newsletter on a monthly basis, with updates on our investments, events we are attending, and significant news from our portfolio companies.